- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Polyrizon beauftragt CRO für Biokompatibilitätsstudien seiner Medizintechnik | - | Investing.com Deutsch | ||
| Di | Polyrizon signs CRO agreement for biocompatibility studies | 1 | Investing.com | ||
| Di | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| Di | Polyrizon Ltd.: Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program | 154 | GlobeNewswire (Europe) | Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen | |
| 10.03. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.03. | Polyrizon Ltd.: Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study | 223 | GlobeNewswire (Europe) | Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen | |
| 26.02. | Polyrizon: Studie zeigt überlegene nasale Deposition von Naloxon-Formulierung | 1 | Investing.com Deutsch | ||
| 26.02. | Polyrizon Ltd.: Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product | 112 | GlobeNewswire (Europe) | Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions... ► Artikel lesen | |
| 26.02. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.02. | Polyrizon plant Übernahme im Privatjet-Sektor - Aktie legt zu | 1 | Investing.com Deutsch | ||
| 10.02. | Polyrizon Ltd.: Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator | 173 | GlobeNewswire (Europe) | The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted... ► Artikel lesen | |
| 06.02. | Polyrizon climbs on Clearmind Deal | - | Baystreet.ca | ||
| 06.02. | Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders | 1 | RTTNews | ||
| 06.02. | Clearmind und Polyrizon kooperieren bei nasaler MEAI-Formulierung | 1 | Investing.com Deutsch | ||
| 06.02. | Clearmind partners with Polyrizon to develop intranasal MEAI formulation | 1 | Investing.com | ||
| 06.02. | Polyrizon to develop intranasal formulation of Clearmind's MEAI drug | 2 | Investing.com | ||
| 06.02. | Polyrizon entwickelt nasale Formulierung für Clearminds Wirkstoffkandidaten MEAI | 1 | Investing.com Deutsch | ||
| 06.02. | Polyrizon Ltd.: Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation | 215 | GlobeNewswire (Europe) | Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06... ► Artikel lesen | |
| 04.02. | Polyrizon intends to acquire 51% stake in global private aviation company | 2 | Seeking Alpha | ||
| 04.02. | Polyrizon signs MOU to acquire 51% stake in Arrow Aviation | 4 | Investing.com |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,570 | -1,94 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen | |
| NOVAVAX | 8,572 | +1,62 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 21,000 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BIOXXMED | 1,210 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,450 | +1,40 % | H.C. Wainwright reiterates Inovio stock rating on FDA review | ||
| COSCIENS BIOPHARMA | 0,795 | -19,70 % | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| XOMA ROYALTY | 24,200 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,180 | -2,48 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office | Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 0,750 | 0,00 % | ORAGENICS INC - 10-K, Annual Report | ||
| VIVUS | - | - | VIVUS B.V.: VIVUS Confirms QSIVA Price Reduction Is Now Effective Across Nordics and Poland | - The lowered pricing structure is now available for 101.82 EUR per bottle at pharmacies throughout Finland
AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical... ► Artikel lesen | |
| TENAX THERAPEUTICS | 11,600 | -4,13 % | Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| SERES THERAPEUTICS | 7,980 | +2,44 % | Seres Therapeutics terminiert Hauptversammlung für den 9. Juni 2026 |
POLYRIZON LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.